癌症内科住院患者医院获得性静脉血栓风险评估模型的开发与验证
该研究基于6个学术健康系统2016至2022年的住院数据,开发并验证了针对活动性癌症内科住院患者的医院获得性VTE风险评估模型。新模型在开发队列和验证队列中的AUC分别为0.68和0.64,校准斜率分别为1.07和0.84,性能优于非癌症特异性模型。
要点
- 新模型预测因子包括既往VTE、营养不良、血液恶性肿瘤(除外侵袭性淋巴瘤)、肺癌、炎症性合并症、年龄、入院时抗凝水平和COPD。
- 开发队列医院获得性VTE发生率为0.6%,验证队列为0.5%。
- 新模型在开发队列AUC为0.68,验证队列AUC为0.64,优于重新拟合的原有模型(AUC 0.60)。
核心结论
- 针对癌症内科住院患者开发的医院获得性VTE风险评估模型性能优于非癌症特异性模型,可支持个体化风险评估。
研究设计与样本
- 多中心回顾性队列研究,纳入6个学术健康系统2016年1月1日至2022年12月31日收治的≥18岁活动性癌症内科住院患者,排除入院时已发生VTE者。
- 先通过加入癌症类型重新拟合原有内科患者RAM,再采用贝叶斯LASSO logistic回归开发新模型。
主要发现
- 开发队列医院获得性VTE发生411例(0.6%),验证队列发生298例(0.5%)。
- 重新拟合原有RAM后,AUC为0.60,校准斜率为0.60。
- 新模型识别出的预测因子及系数:既往VTE(1.08)、营养不良(0.42)、血液恶性肿瘤除外侵袭性淋巴瘤(0.35)、肺癌(0.33)、炎症性合并症(0.41)、年龄≥75岁(-0.55)、年龄60-75岁(-0.07)、入院时抗凝水平(全剂量0.45;预防剂量-0.06)、COPD(-0.04)。
- 新模型在开发队列AUC为0.68、校准斜率1.07;在验证队列AUC为0.64、校准斜率0.84。
临床怎么用
- 该模型可用于活动性癌症内科住院患者的医院获得性VTE个体化风险评估,辅助识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing risk assessment models (RAM) for hospital-acquired venous thromboembolism (VTE) have not been widely assessed in people with cancer or have underperformed. OBJECTIVES: We aimed to develop and validate a RAM for hospital-acquired VTE for patients with active cancer admitted to medical services. METHODS: We included admissions to medical services of adults ≥ 18 years with active cancer at 6 academic health systems from January 1, 2016, to December 31, 2022. We excluded patients with VTE at admission. Four systems formed the development cohort and 2 the validation cohort. First, we refit a prior RAM for medical patients by adding cancer type. Then, we then developed a de-novo RAM using Bayesian least absolute shrinkage and selection operator logistic regression. RESULTS: Among 65 626 development and 58 124 validation admissions, hospital-acquired VTE occurred in 411 (0.6%) and 298 (0.5%), respectively. After refitting the existing RAM, the area under the receiver operating curve and calibration slope were 0.60 and 0.60, respectively. The de-novo model identified predictors (coefficient): prior VTE (1.08), malnutrition (0.42), hematologic malignancy excluding aggressive lymphomas (0.35), lung cancer (0.33), inflammatory comorbidity (0.41), age [≥75, -0.55; 60-75 years, -0.07]), anticoagulation level at admission (full, 0.45; prophylactic, -0.06), and chronic obstructive pulmonary disease (-0.04). The area under the receiver operating curve and calibration slope were 0.68 and 1.07 in the development cohort and 0.64 and 0.84 in the validation cohort, respectively. CONCLUSION: The hospital-acquired RAM developed and validated in this study for patients with cancer performed better than a noncancer-specific model. This tool will support individualized risk assessment in medical in-patients with cancer.
引用
- Martin KA, Wilkinson K, Sparks A, et al. Development and validation of a risk assessment model for hospital-acquired venous thrombosis in medical in-patients with cancer. J Thromb Haemost. 2026. PMID: 42276273. doi:10.1016/j.jtha.2026.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。